Skip to main content
. 2017 Feb 11;8(15):24892–24901. doi: 10.18632/oncotarget.15279

Figure 3. The value of serum MIC-1 in assessment of therapy response and surveillance of CRC recurrence after curative resection.

Figure 3

A. The level of serum MIC-1 in CRC patients before surgery was compared with that of one month after surgical removal of primary tumors (n = 106). And in 20 patients with documented CRC recurrence, the level of serum MIC-1 were significantly elevated (median: 841.2 pg/mL vs 1747.0 pg/mL, mean + SD: 1017+832.1 pg/mL vs 1902+953.5 pg/mL; p<0.001). B. The level of serum MIC-1 in the patients with liver metastasis was compared with non-liver metastasis at the presence of tumor recurrence in 20 relapse patients. More highly elevated levels of serum MIC-1 was occurred 100% among 11 patients with liver metastasis, compared with MIC-1 levels in patients with non-liver metastasis (n=9).